Test Tumor M2-PK

[floema]

Czy ktoś robił sobie taki test,szczególnie po usuniętym guzie rakowym itd.Co
sądzicie o tym nowym teście przesiewowym.
www.tumorm2pk.pl/pl/

[osmanthus]

Tumor M2-PK screening for the early detection of colorectal tumors
and polyps

Preliminary clinical studies in Germany, England and Ireland, which
tested the detection of fecal Tumor M2-PK as a biomarker for the
early detection of colorectal tumors (= bowel cancer), have revealed
sensitivities between 73% (in the only published study) and 97 % (in
an unpublished conference poster presentation). This means that the
test was positive in between 73 and 97 out of every 100 colorectal
tumor patients. For polyps with a diameter larger than 1 cm the
sensitivity was 60 %; for polyps smaller than 1 cm the sensitivity
was about 25 %. The overall sensitivity for all polyps was 40 %.
Most people are more willing to accept non-invasive preventive
medical check-ups. Therefore, the measurement of Tumor M2-PK in
stool samples, with follow-up by colonoscopy to clarify the Tumor
M2-PK positive results, may prove to be an advance in the early
detection of colorectal carcinomas. More research is needed before
the test can be recommended as a screening procedure.
[edit]Tumor M2-PK measurements in cancer follow-up

Studies from various international working groups have revealed a
significantly increased amount of Tumor M2-PK in EDTA-plasma samples
of patients with renal, lung, breast, cervical and gastrointestinal
tumors (oesophagus, stomach, pancreas, colon, rectum), as well as
melanoma (= skin cancer), which correlated with the tumor stage.
The combination of Tumor M2-PK with the appropriate classical tumor
marker, such as CEA for bowel cancer, CA 19-9 for pancreatic cancer
and CA 72-4 for gastric cancer, significantly increases the
sensitivity to detect various cancers.
An important application of the Tumor M2-PK test in EDTA-plasma is
for follow-up during tumor therapy, to monitor the success or
failure of the chosen treatment, as well as predicting the chances
of a “cure” and survival.
If Tumor M2-PK levels decrease during therapy and then remain low
after therapy it points towards successful treatment. An increase in
the Tumor M2-PK values during or after therapy points towards
relapse and/or metastasis.
Increased Tumor M2-PK values can sometimes also occur in severe
inflammatory diseases, which must be excluded by differential
diagnosis.

&


www.nature.com/bjc/journal/v96/n9/full/6603712a.html